CytoMed Therapeutics (GDTC) Equity Ratio (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Equity Ratio for 5 consecutive years, with 0.86 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 4.45% to 0.86 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.86 through Dec 2025, down 4.45% year-over-year, with the annual reading at 0.86 for FY2025, 3.62% down from the prior year.
  • Equity Ratio hit 0.86 in Q4 2025 for CytoMed Therapeutics, down from 0.9 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.91 in Q4 2023 to a low of 0.11 in Q4 2022.
  • Historically, Equity Ratio has averaged 0.64 across 5 years, with a median of 0.86 in 2025.
  • Biggest five-year swings in Equity Ratio: crashed 73.67% in 2022 and later soared 710.47% in 2023.
  • Year by year, Equity Ratio stood at 0.43 in 2021, then crashed by 73.67% to 0.11 in 2022, then skyrocketed by 710.47% to 0.91 in 2023, then dropped by 1.19% to 0.9 in 2024, then decreased by 4.45% to 0.86 in 2025.
  • Business Quant data shows Equity Ratio for GDTC at 0.86 in Q4 2025, 0.9 in Q4 2024, and 0.91 in Q4 2023.